Literature DB >> 15992057

Caspases in apoptotic death.

L Denner1.   

Abstract

Caspases are the central mediators of normal and pathological apoptotic death. They are cysteine proteases that cleave after aspartic acid. The inactive pro-enzymes are proteolytically processed and activated through mechanisms of recruitment to signalling complexes, upstream activator caspases or autoactivation. Many amplifying cascades exist in caspase activation pathways that are evolutionarily conserved. The human caspase family contains at least 10 members which form 3 groups based on substrate specificity, proteolytic targets and functional actions. The crystal structure has been solved for members from two of these groups with inhibitory peptides bound in the active site. These structures have allowed tremendous insight into mechanisms of catalysis, substrate binding and substrate specificity. Enlightened knowledge of enzyme-substrate interactions has led to the design of many inhibitors that are active in animal models of caspase-mediated cell death. Testing in animal models should lead to drugs for therapeutic intervention in the many human diseases characterised by excessive apoptotic cell death.

Entities:  

Year:  1999        PMID: 15992057     DOI: 10.1517/13543784.8.1.37

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  2 in total

1.  Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines.

Authors:  M Rabuffetti; C Sciorati; G Tarozzo; E Clementi; A A Manfredi; M Beltramo
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

2.  Attenuation of increased myocardial ischaemia-reperfusion injury conferred by hypercholesterolaemia through pharmacological inhibition of the caspase-1 cascade.

Authors:  Tzung-Dau Wang; Wen-Jone Chen; Tzan-Jr Mau; Jong-Wei Lin; Wan-Wan Lin; Yuan-Teh Lee
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.